Central Therapeutics
- Biotech or pharma, therapeutic R&D
Central Therapeutics was founded by ADAR1 Partners, a $700M biotech hedge fund, in 2025 to incubate two candidates. Each candidate is a bispecific in I&I with multi-blockbuster potential, an efficient discovery pathway (~$12M to IND per candidate), and each is ~18 months from the clinic.
CTX-001 is a bispecific antibody that creates a disease modifying, functional cure for allergic diseases including allergic asthma, chronic spontaneous urticaria, food allergy, and seasonal rhinitis. CTX-002 is a bispecific antibody that knocks down Th2 and Th1 in atopic dermatitis creating Rinvoq-like efficacy while maintaining a Dupixent-like safety profile. We are the only Th2/Th1 molecule that hits the right epitope to maintain the critical Th1 binding protein negative feedback loop.
We are raising $5M for each candidate largely from internal capital, but would be open to finding the right strategic partner for this early round.
Address
AustinTexas
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}